IMAC vs. ENLV, FBRX, NKGN, SLGL, MOVE, EYEN, APM, ACXP, ALRN, and CERO
Should you be buying IMAC stock or one of its competitors? The main competitors of IMAC include Enlivex Therapeutics (ENLV), Forte Biosciences (FBRX), NKGen Biotech (NKGN), Sol-Gel Technologies (SLGL), Movano (MOVE), Eyenovia (EYEN), Aptorum Group (APM), Acurx Pharmaceuticals (ACXP), Aileron Therapeutics (ALRN), and CERo Therapeutics (CERO). These companies are all part of the "medical" sector.
IMAC (NASDAQ:IMAC) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.
IMAC has higher revenue and earnings than Enlivex Therapeutics.
IMAC received 22 more outperform votes than Enlivex Therapeutics when rated by MarketBeat users. However, 77.78% of users gave Enlivex Therapeutics an outperform vote while only 60.17% of users gave IMAC an outperform vote.
In the previous week, IMAC had 8 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 12 mentions for IMAC and 4 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.33 beat IMAC's score of 0.32 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.
IMAC has a beta of -0.88, indicating that its share price is 188% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500.
24.3% of IMAC shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 10.0% of IMAC shares are held by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Enlivex Therapeutics has a net margin of 0.00% compared to IMAC's net margin of -75.40%. IMAC's return on equity of -52.17% beat Enlivex Therapeutics' return on equity.
Enlivex Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 379.45%. Given Enlivex Therapeutics' higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than IMAC.
Summary
IMAC and Enlivex Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get IMAC News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
